Eligard Information Center

Not an actual patient.

SET YOUR SIGHTS ON FLEXIBILITY, WITH 4 DOSING OPTIONS BASED ON YOUR PATIENTS’ NEEDS

Long-acting treatment options help support continuity while giving patients and practices more flexibility

With 1-, 3-, 4-, and 6-month dosing options, ELIGARD offers more opportunities to align ADT treatment with individual patient needs.2

As little as 2 injections per year

Sustained adherence throughout the entire dosing period

Four dosing options to support individualized care

The unique delivery technology of ELIGARD enables one of the smallest injection volumes available—helping provide less discomfort to your patients3

Illustrative image of 1-month 7.5-mg needle, 3-month 22.5-mg needle, 4-month 30-mg needle, and 6-month 45-mg needle

*Approximate dosing volume.

More dosing options mean more flexibility for you and your patients2,3

Plan your patient's treatment schedule

Dosing Calculator

Use the Dosing Calculator tool to instantly see when your patient is due for their next dose by inputting the date of their latest treatment and prescribed dose.

Last injection date
Choose dose
Appointment date
-
Note
-

FDA approval of the ELIGARD product was based on studies utilizing a 28-day month dosing interval. This dosing calculator is for informational purposes only. Final dosing timing decision is up to the physician’s discretion.

More freedom in injection 
site selection

ELIGARD has multiple subcutaneous (SC) injection site options, giving you greater flexibility in administration2

Illustrative image of front and back of body showing areas with sufficient subcutaneous tissue

The benefits of ELIGARD and SC injection3

More surface area

  • Can be administered anywhere with sufficient SC tissue, not just the abdomen
  • Suitable for patients with lower muscle mass

Flexible patient experience

  • Minimally invasive, avoids local muscle soreness, and appropriate for patients with mobility challenges, including wheelchair users
  • Flexibility in site of care, since it can be administered in semiprivate settings 

Reduced risk of complications

  • Low likelihood of bone and nerve damage and safe for patients on anticoagulants

GET RELIABLE T SUPPRESSION
WITH ELIGARD’s
LONG-ACTING TECHNOLOGY

EXPLORE NOW
ADT, androgen deprivation therapy; LHRH, luteinizing hormone-releasing hormone; T, testosterone.
References: 1. Data on file. IQVIA data, Jan 2025-June 2026. Tolmar, Inc.; 2026. 2. ELIGARD (leuprolide acetate). Prescribing Information. Tolmar, Inc. 2026. 3. Prettyman J, Engel L, Boldt-Houle DM, Atkinson S, Wilt W. Personalizing treatment in the delivery of care by nurses to patients with prostate cancer. Urologic Nursing. 2019;39(2):83-99.
Tap for safety information

IMPORTANT SAFETY INFORMATION

ELIGARD® (leuprolide acetate) for injectable suspension is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer.
ELIGARD is contraindicated in patients with hypersensitivity to GnRH, GnRH agonists, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonists have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate.
Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH agonists in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice. Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis, and erythema multiforme, occurred in patients receiving ELIGARD. Monitor for and advise patients of the signs and symptoms of SCARs. May cause fetal harm.
ELIGARD may impair fertility in males of reproductive potential.
The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported.

Please see full Prescribing Information for ELIGARD.

You are now leaving
ELIGARDhcp.COM

Are you sure you want to leave? 

continue to site
cancel
Skip to content